

SPECTRUM PHARMACEUTICALS INC  
Form 8-K  
January 11, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): January 11, 2016**

**SPECTRUM PHARMACEUTICALS, INC.**  
**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-35006**  
**(Commission**  
  
**File Number)**

**93-0979187**  
**(IRS Employer**  
  
**Identification No.)**

**11500 S. Eastern Ave., Ste. 240, Henderson, NV**

**89052**

**(Address of Principal Executive Offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (702) 835-6300**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On Monday, January 11, 2016, Spectrum Pharmaceuticals, Inc. (Spectrum) announced the signing of an agreement with Servier Canada Inc., to develop and commercialize in Canada four Spectrum hemato-oncology drugs: Zevalin<sup>®</sup> (ibritumomab tiuxetan) Injection for intravenous use, Folutyn<sup>®</sup>(pralatrexate injection), Beleodaq<sup>®</sup> (belinostat) for Injection and Marqibo<sup>®</sup> (vinCRISTine sulfate LIPOSOME injection) for intravenous infusion. Spectrum will receive \$6 million in upfront payments, plus development milestone payments and royalties based on net product sales. The full press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated January 11, 2016.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Spectrum Pharmaceuticals, Inc.**

Date: January 11, 2016

By: /s/ Kurt A. Gustafson  
Kurt A. Gustafson  
Executive Vice President and Chief  
Financial Officer

**Exhibit Index**

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Press Release dated January 11, 2016.